You have free access to this content

Cancer

Cover image for Vol. 118 Issue 8

15 April 2012

Volume 118, Issue 8

Pages 1959–2185

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
  2. Review Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Ultrashort courses of adjuvant breast radiotherapy : Wave of the future or a fool's errand? (pages 1962–1970)

      Atif J. Khan, Roger G. Dale, Douglas W. Arthur, Bruce G. Haffty, Dorin A. Todor and Frank A. Vicini

      Version of Record online: 26 AUG 2011 | DOI: 10.1002/cncr.26457

      A review of current intraoperative and ultrashort radiotherapy schedules for the treatment of breast cancer is presented. Both the promise and the pitfalls of this strategy are reviewed.

    2. You have free access to this content
      18F-fluoro-deoxyglucose positron emission tomography in assessment of myeloma-related bone disease: A systematic review (pages 1971–1981)

      Danielle van Lammeren-Venema, Josien C. Regelink, Ingrid I. Riphagen, Sonja Zweegman, Otto S. Hoekstra and Josée M. Zijlstra

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26467

      • original image

      18F-fluoro-deoxyglucose positron emission tomography–computed tomography is a promising tool for predicting outcome as well as response monitoring in multiple myeloma. However, its efficacy has to be validated in future studies.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer (pages 1982–1988)

      Ana P. Kiess, Heather L. McArthur, Kathleen Mahoney, Sujata Patil, Patrick G. Morris, Alice Ho, Clifford A. Hudis and Beryl McCormick

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26484

      • original image
      • original image
      • original image

      Patients with human epidermal growth factor 2 (HER2)-positive breast cancer have a higher risk of locoregional recurrence, even in the setting of early stage, lymph node-negative disease. This single institution, retrospective study indicates that locoregional failure rates can be reduced markedly with adjuvant trastuzumab in women with lymph node-negative, HER2-positive disease who receive breast-conservation therapy.

    2. You have free access to this content
      MutYH mutation carriers have increased breast cancer risk (pages 1989–1993)

      Gad Rennert, Flavio Lejbkowicz, Ilana Cohen, Mila Pinchev, Hedy S. Rennert and Ofra Barnett-Griness

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26506

      Heterozygosity for the mutY homolog gene MutYH is associated with close to doubling of the risk for breast cancer in a population that has a high prevalence of mutations in this gene. Although some former reports suggested such an association in highly selected cancer families, the authors manage to demonstrate it in a population-based study of the general population. The findings can help identify women at risk for preventive interventions.

    3. You have free access to this content
      Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection (pages 1994–2003)

      Jeremy Setton, Hiram Cody, Lee Tan, Monica Morrow, Clifford Hudis, Jeffrey Catalano, Beryl McCormick, Simon Powell and Alice Ho

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26504

      • original image
      • original image
      • original image
      • original image

      Regional control is high in a large cohort of patients with low-volume sentinel lymph node disease who do not undergo axillary dissection, regardless of the extent of the axillary radiation. Whole-breast radiation alone, including in the prone position, is sufficient treatment after breast-conserving therapy in this select population.

    4. You have free access to this content
      Omission of radiation therapy after breast-conserving surgery in the United States : A population-based analysis of clinicopathologic factors (pages 2004–2013)

      Todd M. Tuttle, Stephanie Jarosek, Elizabeth B. Habermann, Doug Yee, Jianling Yuan and Beth A. Virnig

      Version of Record online: 27 SEP 2011 | DOI: 10.1002/cncr.26505

      • original image
      • original image

      An increasing proportion of patients with breast cancer do not receive radiation therapy after breast-conserving surgery. Factors associated with the omission of radiation therapy include younger patient age, larger tumor size, high tumor grade, lymph node metastases, negative estrogen receptor status, and African American or Hispanic race.

    5. You have free access to this content
      Salvage stereotactic radiosurgery for breast cancer brain metastases : Outcomes and prognostic factors (pages 2014–2020)

      Paul J. Kelly, Nancy U. Lin, Elizabeth B. Claus, Eudocia C. Quant, Stephanie E. Weiss and Brian M. Alexander

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26343

      • original image
      • original image
      • original image
      • original image

      In patients with good Karnofsky performance status, salvage stereotactic radiosurgery (SRS) for breast cancer brain metastases is a reasonable treatment option, given an associated median survival in excess of 9 months. Furthermore, patients with HER2-positive tumors at diagnosis or stable extracranial disease at the time of SRS have an improved clinical course, with median survival of >1 year.

    6. You have free access to this content
      Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers : A comparative effectiveness analysis (pages 2021–2030)

      Kathryn P. Lowry, Janie M. Lee, Chung Y. Kong, Pamela M. McMahon, Michael E. Gilmore, Jessica E. Cott Chubiz, Etta D. Pisano, Constantine Gatsonis, Paula D. Ryan, Elissa M. Ozanne and G. Scott Gazelle

      Version of Record online: 20 SEP 2011 | DOI: 10.1002/cncr.26424

      • original image
      • original image
      • original image
      • original image

      A Markov Monte Carlo simulation model was used to compare the life expectancy gains of various annual breast cancer screening strategies in women with BRCA1/BRCA2 mutations, including the risk of radiation-induced cancers. The results suggest that screening with annual magnetic resonance imaging starting at age 25 years with delayed, alternating digital mammography starting at age 30 years is probably the most effective screening strategy in BRCA mutation carriers.

      Corrected by:

      Erratum: Erratum: Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: A comparative effectiveness analysis

      Vol. 118, Issue 21, 5448, Version of Record online: 20 MAR 2012

    7. You have free access to this content
      Adjuvant therapy in stage I carcinoma of the breast : The influence of multigene analyses and molecular phenotyping (pages 2031–2038)

      Gordon F. Schwartz, Jorge Reis-Fihlo, Lajos Pusztai, Ian S. Fentiman, Roland Holland, Harry Bartelink, Emiel J. T. Rutgers, Lawrence J. Solin, Juan Palazzo and and the Consensus Committee

      Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27431

      An international group of experts debated recommendations for adjuvant hormone and cytotoxic chemotherapy in stage I breast cancers. The findings are presented based on various demographic, morphologic, biologic, and genetic factors expressed by individual tumors.

    8. You have free access to this content
      Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases (pages 2039–2047)

      Naoki Niikura, Jun Liu, Naoki Hayashi, Shana L. Palla, Yutaka Tokuda, Gabriel N. Hortobagyi, Naoto T. Ueno and Richard L. Theriault

      Version of Record online: 2 DEC 2011 | DOI: 10.1002/cncr.26512

      • original image

      Our study demonstrates that for patients with bone-only metastases, zoledronic acid did not prolong progression-free survival (PFS) or overall survival (OS). In patients with bone-only metastasis we did not find antitumor effects of zoledronic acid.

    9. You have free access to this content
      Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort (pages 2048–2058)

      Heather Greenlee, Marilyn L. Kwan, Lawrence H. Kushi, Jun Song, Adrienne Castillo, Erin Weltzien, Charles P. Quesenberry Jr. and Bette J. Caan

      Version of Record online: 27 SEP 2011 | DOI: 10.1002/cncr.26526

      There is concern that antioxidant supplement use during chemotherapy and radiation therapy may decrease treatment effects, yet effects on recurrence and survival are largely unknown. Data from a prospective cohort study of women with early stage breast cancer suggest that long-term effects of antioxidant supplement use after diagnosis likely differ by type of antioxidant.

    10. Genitourinary Disease
      You have free access to this content
      Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer (pages 2059–2068)

      Nirav S. Kapadia, Karin Olson, Howard M. Sandler, Felix Y. Feng and Daniel A. Hamstra

      Version of Record online: 26 AUG 2011 | DOI: 10.1002/cncr.26498

      • original image
      • original image
      • original image
      • original image
      • original image

      Because biochemical failure does not predict for overall survival after radiotherapy (RT) in prostate cancer, a short interval to biochemical failure (defined as <18 months after finishing therapy) is tested as a biomarker for both cause-specific and overall survival. Among 710 patients treated with dose-escalated RT at the University of Michigan, a short interval to biochemical failure is found to be prognostic of both cause-specific and overall survival.

    11. Head and Neck Disease
      You have free access to this content
      A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma (pages 2069–2077)

      Leo A. Niemeier, Haruko Kuffner Akatsu, Chi Song, Sally E. Carty, Steven P. Hodak, Linwah Yip, Robert L. Ferris, George C. Tseng, Raja R. Seethala, Shane O. LeBeau, Michael T. Stang, Christopher Coyne, Jonas T. Johnson, Andrew F. Stewart and Yuri E. Nikiforov

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26425

      • original image
      • original image
      • original image
      • original image

      Thyroid papillary microcarcinoma (TPMC) is a common thyroid tumor with clinical behavior that is difficult to predict. A combined molecular-pathologic risk stratification model based on BRAF mutation status and 3 histopathologic features is a better predictor of extrathyroid spread of TPMC than either mutational or histopathologic findings alone.

    12. Lung Disease
      You have free access to this content
      Stereotactic body radiotherapy using a radiobiology-based regimen for stage I nonsmall cell lung cancer : A multicenter study (pages 2078–2084)

      Yuta Shibamoto, Chisa Hashizume, Fumiya Baba, Shiho Ayakawa, Yoshihiko Manabe, Aiko Nagai, Akifumi Miyakawa, Taro Murai, Hiromitsu Iwata,, Yoshimasa Mori, Mikio Mimura and Satoshi Ishikura

      Version of Record online: 25 AUG 2011 | DOI: 10.1002/cncr.26470

      • original image
      • original image
      • original image
      • original image

      In stereotactic body radiotherapy for 180 patients with stage I nonsmall cell lung cancer, the authors use a higher dose for T2 tumors and use interfraction intervals of at least 3 days. Local control rates (86% for patients with T1 tumors and 73% for patients with T2 tumors) appear to be reasonable.

    13. You have free access to this content
      Functional regulatory variants of MCL1 contribute to enhanced promoter activity and reduced risk of lung cancer in nonsmokers: Implications for context-dependent phenotype of an antiapoptotic and antiproliferative gene in solid tumor (pages 2085–2095)

      Yan Jiang, Wenjing Wang, Jiucun Wang, Ye Lu, Yanmei Chen, Li Jin, Dongxin Lin, Fuchu He and Haijian Wang

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26502

      • original image
      • original image
      • original image
      • original image
      • original image

      MCL1 has dual roles in regulation of both apoptosis and proliferation. This study confirms that MCL1 promoter variants positively affect gene expression and suggests that these functional regulatory variants are associated with reduced risk of lung cancer in nonsmokers.

    14. Neuro-Oncology
      You have free access to this content
      Clinical significance of KISS1 protein expression for brain invasion and metastasis (pages 2096–2105)

      Ilya V. Ulasov, Natalya V. Kaverina, Peter Pytel, Bart Thaci, FeiFei Liu, Douglas R. Hurst, Danny R. Welch, Husein A. Sattar, Olufunmilayo I. Olopade, Anatoly Y. Baryshnikov, Zaira G. Kadagidze and Maciej S. Lesniak

      Version of Record online: 16 SEP 2011 | DOI: 10.1002/cncr.26525

      • original image
      • original image
      • original image
      • original image
      • original image

      This study shows that breast cancer expresses KISS1. Cytoplasmic expression of KISS1 may be used as a prognostic marker for increased risk of breast cancer progression.

    15. Sarcoma
      You have free access to this content
      CAPER-α alternative splicing regulates the expression of vascular endothelial growth factor165 in Ewing sarcoma cells (pages 2106–2116)

      Gangxiong Huang, Zhichao Zhou, Hua Wang and Eugenie S. Kleinerman

      Version of Record online: 25 AUG 2011 | DOI: 10.1002/cncr.26488

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      The overexpression of vascular endothelial growth factor165 in some Ewing tumors may be mediated by a switch from the 189 isoform to the 165 isoform, which is secondary to the down-regulation of CAPER-α. EWS/FLI-1 may control the transcription of CAPER-α, resulting in its down-regulation in Ewing sarcoma cells.

    16. You have free access to this content
      Antimetastatic activity of honokiol in osteosarcoma (pages 2117–2127)

      Patrick Steinmann, Denise K. Walters, Matthias J. E. Arlt, Ingo J. Banke, Urs Ziegler, Bettina Langsam, Jack Arbiser, Roman Muff, Walter Born and Bruno Fuchs

      Version of Record online: 20 SEP 2011 | DOI: 10.1002/cncr.26434

      • original image
      • original image
      • original image
      • original image
      • original image

      Honokiol reduces the formation of lung micrometastases and macrometastases in a subcutaneous LM8 mouse osteosarcoma model. In vitro, honokiol inhibits the proliferation and migration of LM8 cells; and, at higher concentrations, it causes rapid cell death, which is distinct from necrosis, apoptosis, or autophagy.

    17. Discipline

      Clinical Trials
      You have free access to this content
      Randomized controlled trial of acitretin versus placebo in patients at high-risk for basal cell or squamous cell carcinoma of the skin (North Central Cancer Treatment Group Study 969251) (pages 2128–2137)

      Kunal C. Kadakia, Debra L. Barton, Charles L. Loprinzi, Jeff A. Sloan, Clark C. Otley, Brent B. Diekmann, Paul J. Novotny, Steven R. Alberts, Paul J. Limburg and Mark R. Pittelkow

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26374

      • original image
      • original image
      • original image
      • original image

      In this randomized, double-blind, chemoprevention trial, the authors demonstrate that the use of acitretin fails to significantly reduce the incidence or the time to first new nonmelanoma skin cancer in nontransplantation patients with 2 or more previous nonmelanoma skin cancers.

    18. You have free access to this content
      A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome (pages 2138–2147)

      Azra Raza, Naomi Galili, Scott E. Smith, John Godwin, Ralph V. Boccia, Han Myint, Daruka Mahadevan, Deborah Mulford, Mark Rarick, Gail L. Brown, Dale Schaar, Stefan Faderl, Rami S. Komrokji, Alan F. List and Mikkael Sekeres

      Version of Record online: 1 SEP 2011 | DOI: 10.1002/cncr.26469

      • original image

      Ezatiostat is the first glutathione analog prodrug glutathione S-transferase P1-1(GSTP1-1) inhibitor shown to cause clinically significant and sustained reduction in red blood cell (RBC) transfusions, transfusion independence, and multilineage responses in myelodysplastic syndrome (MDS) patients. The tolerability and activity profile of ezatiostat may offer a new treatment option for patients with MDS.

    19. Diagnostic Imaging
      You have free access to this content
      Optical fiber-based in vivo quantification of growth factor receptors (pages 2148–2156)

      Thommey P. Thomas, Yu-Chung Chang, Jing Yong Ye, Alina Kotlyar, Zhengyi Cao, Rameshwer Shukla, Suyang Qin, Theodore B. Norris and James R. Baker Jr

      Version of Record online: 25 AUG 2011 | DOI: 10.1002/cncr.26487

      • original image
      • original image
      • original image
      • original image
      • original image

      The paper describes the in vivo quantification of human epidermal growth receptor 2 using a minimally invasive 2-photon optical fiber fluorescence detection technique. The proof of concept for the simultaneous in vivo quantification of multiple receptors is provided.

    20. Disparities Research
      You have free access to this content
      Is public communication about end-of-life care helping to inform all? Cancer news coverage in African American versus mainstream media (pages 2157–2162)

      Jessica M. Fishman, Thomas Ten Have and David Casarett

      Version of Record online: 22 SEP 2011 | DOI: 10.1002/cncr.26499

      African American news media are less likely than mainstream news media to portray negative cancer outcomes and end-of-life care. Given media's segmented audiences, these findings raise concerns that not all audiences are being informed equally well.

    21. Epidemiology
      You have free access to this content
      Adult glioblastoma multiforme survival in the temozolomide era: A population-based analysis of Surveillance, Epidemiology, and End Results registries (pages 2163–2172)

      Amy S. Darefsky, Joseph T. King Jr. and Robert Dubrow

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26494

      • original image
      • original image

      In the United States, there has been a modest, but meaningful, progressive survival improvement among adult glioblastoma multiform patients diagnosed at all ages except 80+ years, starting with cases diagnosed in 1999-2001 and continuing through cases diagnosed in 2005-2007. This improvement coincided with the progressive, widespread adoption of temozolomide for glioblastoma treatment that also started in 1999.

    22. Translational Research
      You have free access to this content
      Identification of novel immunogenic human leukocyte antigen-A*2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer (pages 2173–2183)

      Sunphil Jang, Young Tae Kim, Hye Won Chung, Kyoung-Ryul Lee, Jong-Baeck Lim and Kyungwon Lee

      Version of Record online: 14 SEP 2011 | DOI: 10.1002/cncr.26468

      • original image
      • original image
      • original image
      • original image
      • original image

      Peripheral blood mononuclear cells (PBMCs) and CD8+ cytotoxic T lymphocytes sensitized with newly identified human papillomavirus type 16 E761-69 and E767-76 epitopes for human leukocyte antigen-A*2402 have cytolytic activity and antitumor effects against cervical cancer. Treatment with cisplatin followed by peptide-sensitized PBMCs generates a more potent and long-term antitumor effect than treatment with cisplatin alone.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Review Articles
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      Adjuvant chemotherapy improves survival in patients with American Joint Committee on Cancer stage II colon cancer (page 2184)

      Johannes Betge, Cord Langer and Peter Rehak

      Version of Record online: 31 AUG 2011 | DOI: 10.1002/cncr.26493

      Corrected by:

      Erratum: Erratum

      Vol. 118, Issue 24, 6301, Version of Record online: 6 JUN 2012

    2. You have free access to this content

SEARCH

SEARCH BY CITATION